Abiraterone acetate and prednisolone are recommended to be available as a routine commissioning treatment option for high-risk, hormone sensitive, non-metastatic prostate cancer (newly diagnosed high-risk or relapsing with high-risk features) within the criteria set out in this policy. The use of abiraterone acetate in this indication is off-label.

This policy is restricted to adults as this reflects the population affected by prostate cancer.